trending Market Intelligence /marketintelligence/en/news-insights/trending/FCAOBQdGX6ChqgBzbb0-Xw2 content esgSubNav
In This List

US FDA approves Relmada's application for antidepressant drug

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


US FDA approves Relmada's application for antidepressant drug

Relmada Therapeutics Inc. said the U.S. FDA cleared the company's investigational new drug application for d-Methadone, its novel, N-methyl-D-aspartate receptor antagonist.

D-Methadone is a rapid acting, oral agent for the treatment of depression, neuropathic pain and other potential central nervous system pathological conditions.

The company can now advance the development program for d-Methadone to a phase 2a proof-of-concept clinical study in patients with treatment-resistant depression.